Almac Group Scoops Research & Development Achievement at 2018 Irish Pharma Industry Awards
October 24, 2018
Craigavon, N.I., 24 October 2018 – Following the success of picking up last year’s ‘Export Achievement’ award, Almac Group, the global contract development and manufacturing organization, is delighted to announce it has won the Research & Development Achievement Award during this year’s Irish Pharma Industry Award ceremony. This award recognizes the company’s commitment to delivering the highest quality R&D services to its global clients.
An independent panel, which comprised 14 industry leaders, judged the entries and determined the winners based on a number of key attributes. Almac’s entry was selected as the winner due to its highly effective and innovative selectAZyme™ research program which offers green, economic, robust, scaleable and reliable processes for synthesis of chiral APIs and intermediates. It was one of 24 awards presented during the event.
“We are honored to receive the Research and Development award which once again showcases the successful integration of the diverse and highly skilled technical workforce of Almac and Arran.” Commented Dr Stephen Barr, Managing Director, Almac Sciences. “This award serves to highlight our team’s dedication and commitment to quality and also showcases our ability to solve complex technical challenges. We’re grateful for this award and look forward to drive further success with our continued focus on a range of R&D programs.”
Since launching in 2014, the Pharma Industry Awards recognize the successes and achievements of Ireland’s pharmaceutical industry and are seen as the benchmark for excellence for those operating within the sector. The winners were revealed at a Gala Awards dinner on 23rd October at The Clayton Hotel, Dublin.
Additionally, Almac Clinical Services’ team was a shortlist-nominee for the Supply Chain Achievement Award, which spotlighted their success with having extensive global coverage and expertise in servicing end-to-end supply chain management.
The Pharma Industry Awards celebrates individuals and companies who most distinguish themselves and demonstrate a commitment to innovative solutions and exemplary quality in the Irish Pharma sector. Ranging from process and formulation to contract-development and manufacturing services, these awards allow recipients to showcase their strengths and annual investments. Almac last received the R&D achievement award in 2014 for its work on Almac Diagnostic Services’ proprietary DNA Damage Repair Deficiency (DDRD) test which helps predict which breast cancer patients are likely to benefit from chemotherapy based on their genetic make-up.
About Almac Group
‘Partnering to Advance Human Health’
The Almac Group is an established contract development and manufacturing organization providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally.
Its innovative services range from R&D, biomarker discovery development and commercialization, API manufacture, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organization which has grown organically over the past five decades now employing over 5,000 highly skilled personnel across 17 facilities including Europe, the US and Asia. Click here to view our facilities.
The company has a global reputation for excellence built over 50 years of client service, delivering expertise right across the drug development lifecycle and offering a tailored solution to each of our clients.